バイオ統計学･臨床疫学
Biostatistics and Clinical Epidemiology
教 授 折笠 秀樹 Hideki Origasa
◆ 原 著
1) Inomata M., Kawagishi Y., Tokui K., Masaki Y., Taka C., Kambara K.,Okazawa S., Imanishi S., Ichikawa T., Suzuki K., Yamada T., Sumi S., Origasa H., Matsui S., Hayashi R., and Tobe K. : A history of ischemic heart disease is common cause of wheezing in the elderly of a Japanese local community. Intern. Med., 50: 2975-2981, 2011.（前年度抜け）
2) Fukushima T., Urasaki Y., Yamaguchi M., Ueda M., Morinaga K., Haba T., Sugiyama T., Nakao S., Origasa H., Umehara H., and Ueda T. : A randomized comparison of modified intermediate-dose Ara-C versus High-dose Ara-C post remission therapy for acute myeloid leukemia. Anticancer Res., 32: 643-647, 2012.
3) Sasaki J., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., Itakura H., Hishida H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K., Matsuzawa Y., for the JELIS Investigators. : Relationship between coronary artery disease and LDL-C and/or non HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients under treatment with statins: sub- analysis of the Japan EPA Lipid Intervention Study (JELIS). J. Atheroscler. Thromb., 19: 194-204, 2012.
4) Masuyama S., Tsujino T., Origasa H., Yamamoto K., Akasaka T., Hirano Y., Ohte N., Daimon T., Nakatani S., and Ito H. : Superiority of long-acting to short-acting loop diuretics in treatment of congestive heart failure: the J-MELODIC study. Circ. J., 76: 833-842, 2012.
5) Nakamura S., Sugiyama T., Matsumoto T., Iijima K., Ono S., Tajika M., Tari A., Kitadai Y., Matsumoto H., Nagaya T., Kamoshida T., Watanabe N., Chiba T., Origasa H., Asaka M., for the Japan GAST Study Group. : Long-term outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicenter cohort follow-up study of 420 patients in Japan. Gut, 61: 507-513, 2012.
6) Suzuki N., Sato M., Houkin K., Terayama Y., Uchiyama S., Daida H., Shigematsu H., Goto S., Tanaka K., Origasa H., Miyamoto S., Minematsu K., Matsumoto M., and Okada Y. : One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after Stroke) Registry. J. Stroke Cerebrovasc. Dis., 21: 245-253, 2012.
7) Ibuki K., Watanabe K., Yoshimura N., Kakimoto T., Matsui M., Yoshida T., Origasa H., and Ichida F. : The improvement of hypoxia correlates with neuroanatomical and developmental outcomes: comparison of midterm outcomes in infants with transposition of great arteries or single-ventricle physiology. J. Thorac.
Cardiovasc. Surg., 143: 1077-85, 2012.
8) Itakura H., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K., Matsuzawa Y., for the JELIS Investigators. : The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. J. Atheroscler. Thromb., 19: 673-679, 2012.
9) Yamashita T., Koretsune Y., Yasaka M., Inoue H., Kawai Y., Yamatuchi T., Uchiyama S., Matsumoto M., Ogawa S (Origasa H., data and safety monitoring board member, appeared in Appendix) : Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Circ. J., 76: 1840-1847, 2012.
10) Shinohara Y., Origasa H. : Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors : Results of a meta-analysis of five studies in Asians. Adv. Ther., 29: 900-912, 2012.
11) Kamouchi M., Kumagai N., Okada Y., Origasa H., Yamaguchi T., Kitazono T., for the FSR Investigators. : A risk score for predicting recurrence in patients with ischemic stroke: The Fukuoka stroke risk score for Japanese. Cerebrovasc. Dis., 34: 351-357, 2012.
12) Zhu Y., Origasa H., Luo X., Wang Y., Di J., and Lin L. : Responsiveness of three subjective report of outcome
measures for chronic heart failure. Journal of Chinese Integrative Medicine, 10: 1375-1381, 2012.
13) 許 鳳浩, 上馬場和夫, 小川弘子, 御影雅幸, 折笠秀樹 : 漢方薬の代謝への作用の個人差：防風通聖散の二重盲検
ランダム比較試験. 東方医学, 28: 37-59, 2012.
◆ 総 説
1) 折笠秀樹 : 服薬遵守を立証した JELIS 試験. 循環 Plus, 12: 10-12, 2012.
2) 折笠秀樹 : 臨床研究デザインの初歩. Jpn. J. Rehabil. Med., 49: 177-182, 2012.
◆ 学会報告
1) Matsumoto M., Yamawaki T., Ohtsuki T., Hosomi N., Fukushima M., Nagai Y., Minematsu K., Yokota C., Origasa H., Uchiyama S., and Ibayashi S. : Present status of J-STARS and substudies. International Stroke Conference, 2012, 2, 18-20, New Orleans.
2) Toda E., Lip GYH., Uchiyama S., Shimada K., Origasa H., Kobayashi H., Kawamura A., Kitagawa K., Nagao T., Ikeda Y., Goto S., for the J-TRACE Investigators. : Use of the CHADS2 and CHADS2-VASC score in Japanese patients with atrial fibrillation: A sub-analysis of the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). American College of Cardiology, 2012, 3, 24-27, Chicago.
3) Yamanaka H., Yamamoto K., Takeuchi T., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Shoji T., Sakamaki Y., Miyasaka N., and Koike T. : Certrolizumab pegol improved physical function, pain and health-related quality of life in Japanese patients with active rheumatoid arthritis with concomitant methotrexate: results from the JRAPID study. EULAR Congress 2012, 2012, 6, 6-9, Berlin.
4) Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Iwai K., Miyasaka N., Koike T., and Sakamaki Y. : Certolizumab pegol improved physical function, pain and health-related quality of life in Japanese patients with active rheumatoid arthritis in whom methotrexate could not be administered: results from the Hikari study. EULAR Congress 2012, 2012, 6, 6-9, Berlin.
5) Toda E., Uchiyama S., Shimada K., Origasa H., Kobayashi H., Kawamura A., Kitagawa K., Nagao T., Ikeda Y., Goto S., for the J-TRACE Investigators. : One year event rate of serious thrombosis and bleeding in Japanese patients with myocardial infarction, stroke and atrial fibrillation: results from the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). 58th Annual Meeting of the ISTH, 2012, 6, 27-30, Liverpool.
6) Toda E., Lip GYH., Uchiyama S., Shimada K., Origasa H., Kobayashi H., Kawamura A., Kitagawa K., Nagao T., Ikeda Y., Goto S., for the J-TRACE Investigators. : Predictive Value of CHADS2 score for death, stroke, and myocardial infarction both in patients with or without atrial fibrillation: results from the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). ESC Congress 2012, 2012, 8, 25-29, Munich.
7) Daida H., Miyauchi K., on behalf of the PACIFIC Registry Investigators (Origasa H is one of the PACIFIC Registry Investigators). : The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischaemic Coronary attack) Registry: Final follow-up data of a 2-year study in patients initially hospitalized with acute coronary syndrome in Japan. ESC Congress 2012, 2012, 8, 25-29, Munich.
8) Origasa H., Hashimoto M., Miyajima M., and Arai H. : Quality of life assessment in patients with idiopathic normal pressure hydrocephalus. ISOQOL(International SOciety for Quality Of Life research) 19th Annual Conference, 2012, 10, 24-27, Budapest.
9) Takeuchi T., Yamamoto K., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Shoji T., Miyasaka N., and Koike T. : Clinical response at 12 weeks predicts long-term remission and the extent of radiographic progression in Japanese patients with rheumatoid arthritis treated with certolizumab pegol with and without methotrexate coadministration. 2012 ACR/ARHP Annual Meeting, 2012, 11, 9-14, Washington DC.
10) Tanaka Y., Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Eguchi K., Watanabe A., Origasa H., Shoji T., Miyasaka N., and Koike T. : Long-term safety and efficacy of certolizumab pegol in Japanese rheumatoid arthritis patients in whom methotrexate could not be administered: 52 week results from open label extension
study. 2012 ACR/ARHP Annual Meeting, 2012, 11, 9-14, Washington D.C.
11) 橋本正明, 新井 一, 宮嶋雅一, 伊達 勲, 松前光紀, 折笠秀樹 : 特発性正常圧水頭症の前向き臨床観察研究（Ｊ ＳＲ）の成果と今後の提案. 第 13 回日本正常圧水頭症学会, 2012, 2, 11, 大阪. [第 13 回日本正常圧水頭症学会 記録集, p.31, 2012.]
12) Higashi Y., Fujita M., Origasa H., Miyata T., Matsuo H., Naritomi H., Shigematsu H., on behalf of the SEASON Investigators. : Prospective surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan (SEASON) interim report: results from registration data. 第 76 回日本循環器学会総会, 2012, 3, 16-18, 福岡.
13) Inoue H., Atarashi H., Okumura K., Yamashita T., Origasa H., for the J-RHYTHM Registry. : Optimal anticoagulation levels for prevention of thromboembolic events in patients with atrial fibrillation: a result of J- RHYTHM Registry. 第 76 回日本循環器学会総会, 2012, 3, 16-18, 福岡.
14) Masuyama T., Tsujino T., Origasa H., Yamamoto K., Akasaka T., Hirano Y., Ohte N., Daimon T., Nakatani S., and Ito H. : Comparison of long- and short-acting loop diuretics in congestive heart failure. 第 76 回日 本循環器学会総会[Late Breaking Clinical Trials], 2012, 3, 16-18, 福岡.
15) Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Iwai K., Miyasaka N., Koike T., and Sakamaki Y. : Certolizumab Pegol はメトトレキサートを投与できない活動性 リウマチ患者の身体機能及び健康関連 QOL を改善する：HIKARI 試験. 第 56 回日本リウマチ学会総会, 2012, 4, 26-28, 東京.
16) Yamanaka H., Yamamoto K., Takeuchi T., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Shoji T., Sakamaki Y., Miyasaka N., and Koike T. : メトトレキサートによる効果不十分な日本人関節リウマチ患者に 対する Certolizumab pegol の効果；JRAPID 試験. 第 56 回日本リウマチ学会総会, 2012, 4, 26-28, 東京.
17) 折笠秀樹 : 2 型糖尿病患者におけるインスリン使用実態調査（Insulin Insights）の特徴―臨床疫学的な観点から.
第 55 回日本糖尿病学会年次学術集会・ランチョンセミナー31, 2012, 5, 18, 横浜. [招聘講演]
18) 折笠秀樹 : 生物学的同等性判定の統計学. 日本製剤学会第 27 年回・ラウンドテーブルセッション 3（生物学的同
等性試験の科学的評価）, 2012, 5, 25, 神戸. [招聘講演]
19) 宮田哲郎, 藤田正俊, 折笠秀樹, 東 幸仁, 松尾 汎, 成冨博章, 重松 宏 : 日本の日常臨床における閉塞性動 脈硬化症の患者背景―多施設前向きコホート研究 SEASON の登録データより―. 第 53 回日本脈管学会総会, 2012, 10, 11-13, 東京. [脈管学, 52(Suppl): S116, 2012.]
20) 折笠秀樹 : 癌の臨床研究に必要な統計知識. 第 62 回日本泌尿器科学会中部総会/IJU 教育セミナー, 2012, 11, 1, 富山. [招聘講演]
21) 李 淳馨, 折笠秀樹, 熊谷直子, 城川美佳, 中川 肇, 戸邉一之, 布施秀樹 : 2 型糖尿病治療薬ピオグリタゾンと 膀胱がん発症との関係について―病院診療データベースを用いた実証研究―. 第 33 回日本臨床薬理学会学術総会, 2012, 11, 29 -12, 1, 那覇.
◆ その他
1) 折笠秀樹 : 藤田先生の回想記. 「藤田利治先生 遺稿・追悼文集」藤田利治著, 82, 統計数理研究所, 東京, 2012.
2) 橋本正明, 新井 一, 宮嶋雅一, 伊達 勲, 松前光紀, 折笠秀樹 : 特発性正常圧水頭症の前向き臨床観察研究
(JSR)の成果と今後の提案. 厚生労働省科学研究費補助金（難治性疾患克服研究事業）平成 23 年度総括・分担研究 報告書, 65-67, 2012.
3) 折笠秀樹, 松岡 浄, 熊谷直子 : 正常圧水頭症患者の QOL に関する横断調査. 厚生労働省科学研究費補助金（難治 性疾患克服研究事業）平成 23 年度総括・分担研究報告書, 68-70, 2012.
4) 折笠秀樹 : 最近の糖尿病に関する研究論文：医学統計の視点から. リリーブラッシュアップセミナー2012-春,
2012, 4, 8, 東京. (招聘講演)
5) 折笠秀樹 : 臨床試験を正しく評価するためには. 第 19 回創薬育薬セミナー, 2012, 9, 28, 松山. （招聘講演）
